Eyenuk, a Los Angeles, CA-based artificial intelligence (AI) digital health company, raised $26M in Series A funding.
The round, which brings total funding to over $43m, was led by AXA IM Alts with participation from T&W Medical A/S, A&C Foelsgaard Alternativer ApS, Kendall Capital Partners, and KOFA Healthcare. As part of the capital raise, Rob Binney has joined the Eyenuk Board of Directors as the Board’s Chair. Binney is a veteran executive with 25 years of combined senior leadership experience in the medical device and pharmaceutical industries. Also joining the board are Zina Affas Besse, and Marie-Louise Little, Director of Strategy and Business Development at T&W Medical A/S.
The company intends to use the funds to expand its AI product platform with additional disease indications and advanced care coordination, and to accelerate the platform’s global commercialization and adoption.
Led by CEO and Founder Kaushal Solanki, Eyenuk is an artificial intelligence (AI) digital health company providing an AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. The company is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer’s disease. Its flagship EyeArt AI system has been more broadly adopted worldwide than any other autonomous AI technology for ophthalmology. Since its FDA clearance in 2020, the EyeArt system has been used in over 200 locations in 18 countries, including 14 U.S. states, to screen over 60,000 patients and counting. It was cleared by the FDA for autonomous detection of both referable and vision-threatening diabetic retinopathy without any eye care specialist involvement. The EyeArt system is reimbursed by Medicare in the US, and has regulatory approvals globally, including CE Marking, Health Canada license, and approvals in multiple markets in Latin America and the Middle East.
FinSMEs
17/10/2022